detalimogene voraplasmid
·Code: EG-70
detalimogene voraplasmid: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| ENGENE HOLDINGS INC. (ENGN) | Phase 2 |
FDA Decisions
FDA_MeetingPrimary endpoint for Cohort 1 changed to complete response at any time, consistent with other recent programs for BCG-unresponsive NMIBC.(ENGN)
Frequently asked questions
Who is developing detalimogene voraplasmid?
detalimogene voraplasmid is being developed by ENGENE HOLDINGS INC..
What is detalimogene voraplasmid's latest FDA decision?
The most recent tracked FDA decision for detalimogene voraplasmid is FDA_Meeting for Primary endpoint for Cohort 1 changed to complete response at any time, consistent with other recent programs for BCG-unresponsive NMIBC..
Get deeper analysis on detalimogene voraplasmid
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis